RxSight, Inc. - Common Stock (RXST)

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

RxSight revised its FY25 revenue outlook below estimates, with Q1 sales lagging expectations. BofA downgraded the stock, citing slowing growth and risks ahead.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

RxSight shares down premarket on revised FY25 outlook. CEO cites headwinds in premium IOL market and economy.

On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91.